The effect of human immunodeficiency virus (HIV) infection on cd4 t-lymphocyte depletion among people living with HIV and AIDS in Enugu, Nigeria. by Ohotu, E. O et al.
Ohotu et al, IJBAIR, 2016, 5(1): 2 – 7.
2
International Journal of Basic, Applied and Innovative Research
IJBAIR, 2016, 5(1): 2 - 7
www.arpjournals.com; www.antrescentpub.com
RESEARCH PAPER 
THE EFFECT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION ON 
CD4 T-LYMPHOCYTE DEPLETION AMONG PEOPLE LIVING WITH HIV AND 
AIDS IN ENUGU, NIGERIA.
Ohotu, E. O1., Okafor, G.O2, and Mgbachi, N.G.3, Odurukwe, O.U.4, 
Ohotu, B.O.5
1Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Enugu, Nigeria. 2Department of 
Medical Laboratory Sciences, Faculty of Health Sciences, University of Nigeria, Enugu Campus. 3Department of Medical 
Microbiology, University of Nigeria Teaching Hospital, Enugu, Nigeria.4Department of Medical Rehabilitation, Faculty of 
Health Sciences, University of Nigeria, Enugu Campus. 5Nursing Science Division, University of Nigeria Teaching 
Hospital, Enugu, Nigeria.
Corresponding Author: ohotuedwin@yahoo.com
Received: 20th November, 2015 Accepted: 15th February, 2016 Published: 31st March, 2016
Endorsed By: Innovative Science Research Foundation (ISREF) and International Society of Science Researchers (ISSCIR). 
Indexed By: African Journal Online (AJOL); Texila American University; Genamics; Scholarsteer; EIJASR; CAS-American Chemical 
Society; and IRMS Informatics India (J-Gate)
ABSTRACT
This study evaluated the effect of HIV infection on CD4 T-lymphocyte depletion in people living with HIV/AIDS. Ninety 
(90) subjects recruited into this study were grouped into three -Diagnostic HIV positive (A), HIV positive subjects (B) on 
antiretroviral drugs (HAART) and HIV negative subjects (C) used as control group. Quantitative estimation of HIV load 
was carried out with Real-Time PCR, while CD4 and CD8 T-lymphocyte estimation was carried out using C6 Acurri flow 
cytometer system. Statistical analysis was done with Mann-Whitney test, Kruskal-Wallis statistic and Dunn’s Multiple 
Comparison Test at p < 0.05 as significant. There was significant reduction in mean CD4 T-lymphocyte counts in groups A 
(246.60186.10) and B (255.40168.70), while significant reduction in CD8 T-lymphocyte count occurred only in group A
(449.20273.50). CD4/CD8 ratio reduced significantly in both A (0.770.66) and B (0.650.47), while the mean viral load 
of group B (145591.00259499.00) was significantly reduced when compared with that (24407.00106479.00) of group 
A. Though there was down regulation of viral burden during highly active antiretroviral therapy (HAART), there was no 
corresponding increase in T-cell proliferation. This indicates that there might be a qualitative defect imparted on the 
progenitor cells of CD4 T-lymphocytes during progressive HIV disease. 
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INTRODUCTION
Human Immunodeficiency Virus (HIV) is the causative agent of the fatal condition known as Acquired Immunodeficiency 
Syndrome (AIDS) (Weiss, 1993; Douck et al., 2009); a condition in man in which the immune system begins to fail, 
leading to life-threatening opportunistic infections. HIV infection occurs by a transfer of blood, semen, vaginal fluid, pre-
ejaculate, breast milk, or other body fluids, contaminated with the virus, to a new host. The four major routes of 
transmission are unprotected sex, contaminated needles, breast milk and prenatal transmission. Screening of blood products 
for HIV has largely eliminated transmission through blood transfusion in the developed world, though in Nigeria, it still 
accounts for the second largest source of HIV infection after heterosexual sex (FRN, 2012).
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However, it was estimated that from the discovery of HIV infection in 1981, to the year 2006, AIDS had killed more than 
25 million people worldwide and infected about 0.6% of the world population. In 2005 alone, AIDS claimed an estimated 
2.4 – 3.3 million lives, of which more than 570,000 were children. One third of these deaths occurred in sub-Saharan 
Africa, retarding economic growth and increasing poverty (UNAIDS and WHO, 2010). HIV infects primarily vital cells in 
the human immune system such as helper T-cells (especially CD4+ T-cells), macrophages, and dendritic cells (Cunningham 
et al., 2010). HIV infection leads to low level of CD4+ T-cells through three main mechanisms which include direct viral 
killing of infected cells, increased rate of apoptosis in infected cells and killing of infected CD4+ T-cells by CD8 cytotoxic 
T-lymphocytes. When CD4+ T-cell number decline below a critical level, cell–mediated immunity is lost, and the body 
becomes progressively more susceptible to opportunistic infections. Most untreated people infected with HIV–1 eventually 
develop AIDS (Migueles and Connors, 2010).
Moreover, the failure of the immune system to contain HIV is related to the functional impairment of HIV-specific CD4+
and CD8+ T-cells that accompany the progression of HIV infection (Day et al., 2006).  It is the role of CD4+ T-cells to 
signal other cells of the immune system to perform their respective functions (Deck et al., 2004; Ondoa et al., 2005) by 
secreting cytokines which are involved in signal transduction. The deterioration of T-cell responses or T-cell exhaustion in 
HIV infection involves the early loss of proliferative capacity, cytotoxic potential and the ability to produce interleukin-2 
(Kostense et al., 2002). 
Considering the importance of CD4 T-lymphocyte in the overall immune response, and devastative effect of HIV on CD4 
T-lymphocytes during HIV disease, this study was designed to assess the depletive effect of HIV on CD4 T-lymphocytes 
and the capacity of highly active antiretroviral therapy (HAART) to restore the effect during drug intervention.
MATERIALS AND METHODS
Study Design: A total of ninety (90) subjects were included in this study which has three groups with thirty (30) subjects 
in each study group. The groups include thirty (30) HIV-1 positive subjects that have not started receiving antiretroviral 
drugs, thirty (30) HIV-1 positive subjects on Highly Active Antiretroviral Therapy (HAART) and thirty (30) apparently 
healthy individuals that have tested negative for antibodies to HIV-1 and 2, used as control group. The test subjects were 
recruited from HIV/AIDS patients attending clinics at the University of Nigeria Teaching Hospital Ituku–Ozalla, Enugu 
State University Teaching Hospital (Park Lane), Annunciation Specialist Hospital Emene and Mother of Christ Specialist 
Hospital, all in Enugu, Nigeria. Control subjects were recruited from member of the public, students and staff of the 
hospitals stated above. Sample collection was completed within three months.
Inclusion and Exclusion Criteria: Qualification for recruitment into this study was based on the outcome of oral-
interview/questionnaire, clinical and laboratory assessments. Each person recruited after the assessment, was included as a 
participant after an informed consent has been duly signed. The research considered only those on first line HAART drug 
combination and basically those on Zudovudine, lamivudine and nevirapine drug combination. With the approval of the 
ethics committee, the research was carried out at the Immunology Research Unit of the Department of Haematology and 
Immunology, University of Nigeria Teaching Hospital, Ituku–Ozalla, Enugu State.
Ethical Consideration: Ethical approval was obtained from the Medical Research Ethics Committee of the University of 
Nigeria Teaching Hospital, Ituku-Ozalla, Enugu. After critical study of the research proposal, a written approval was 
signed by the Committee. Each member of the recruited subjects read and signed the informed consent before enrollment 
as a participant. 
Blood Sample Collection: A total of 5mls of blood was collected from each subject using dipotassium ethylendiamine 
tetra-acetic acid (EDTA) bottle. The samples were maintained at 2 to 80C temperature range, and transferred immediately 
to the laboratory for analysis. After pre-analytical procedure, the sample aliquots were stored according to the analytical 
procedure for each variable. 500l of the whole blood was delivered into 2ml cryovial and stored in liquid nitrogen for 
cluster of differentiation (CD) marker studies. The remaining whole blood was separated into plasma and packed cells. The 
plasma sample was frozen at -850C for viral load estimation.
Sample Analysis: HIV screening test was carried out with Genscreen ULTRA HIV Screening Kit for the detection of HIV 
P24 Antigen and Antibodies to HIV–1 and HIV–2 in Human Plasma by Enzyme Immunoassay (BIO–RAD). The 
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GenscreenTM ULTRA HIV Ag–Ab is an enzyme immunoassay based on the principle of the sandwich technique for the 
detection of HIV antigen and various antibodies associated with HIV–1 and / or HIV–2 virus in human serum or plasma. 
HIV–1/2 Confirmatory Test was done with Quali Code HIV–1/2 Kit, from Immunetics Inc. The Quali Code HIV–1/2 kit is 
a Qualitative Immunoblot Assay on the Western Blotting Principle. HIV RNA Extraction was carried out using Thermo 
Scientific Viral RNA Purification Kit from Thermo Fisher Scientific Inc while estimation of HIV Viral Load was done 
with Real Time-PCR method and TaqMan Chemistry. CD4 and CD8 T-lymphocyte levels were estimated using Accuri 
cytometer (C6 flow cytometer system). A beam of light (usually laser light) of a single wavelength is directed onto a 
hydrodynamically focused stream of liquid to form both forward and side scatter. The combination of scattered and 
fluorescent light is picked up by a detector system to analyze and differentiate various types of structures of individual 
particle.
Statistical Analysis:  Kruskal-Wallis statistic and Dunn’s Multiple Comparison Test were used to test for levels of 
significance in CD4 and CD8 T-lymphocyte concentrations, while Mann-Whitney test was used to test for viral load. The 
levels of significance were set at p < 0.05. 
RESULT
The results showed that the mean value of CD4+ T-lymphocyte count in diagnostic HIV positive subjects (246.60186.10) 
was significantly reduced (P<0.05) in comparison with that of the HIV seronegative control subjects (996.40  207.10) (see
Table 1).
Table 1: CD4+ T-lymphocyte levels in diagnostic HIV positive subjects, HIV positive subjects on ARV drugs and 
HIV Seronegative control subjects.
Parameters (cells/l) Diagnostic HIV ARV Drugs HIV 
Seronegative
Median 177.00 202.50 976.50
Mean 246.60 255.40 996.40
Standard Deviation 186.10 168.70 207.10
Minimum 85.00 97.00 681.00
Maximum 920.00 819.00 1366.00
Normality Yes Yes Yes
Table’s statistics for Dunn's Multiple Comparison Test: (1) Diagnostic (246.60186.10) vs ARV (255.40168.70); 
Difference in rank sum =-3.367 (P > 0.05). (2) Diagnostic (246.60186.10) vs Control (996.40207.10); Difference
in rank sum = -45.58 (P < 0.05). (3) ARV (255.40168.70) vs Control (996.40207.10); Difference in rank sum = -
42.22 (P < 0.05).
Also, the mean CD4+ T-lymphocyte count of HIV positive subjects on antiretroviral drugs (255.40168.70) showed 
statistically significant difference (P<0.05) from that of the control group (996.40207.10). However, at 5% level of 
significance, there was no statistically significant difference observed when the mean CD4+ T-lymphocyte count of 
diagnostic HIV positive subjects (246.60186.10) was compared with that of the HIV positive subjects on antiretroviral 
drugs (255.40168.70) (p>0.05) (see Table 1).
On the other hand, the mean CD8+ T-lymphocyte count of diagnostic HIV positive subjects (449.20273.50) in comparison 
with that of the HIV positive subjects on ARV drugs (463.80208.10) showed no significant difference (p>0.05) (see Table 
2). 
Furthermore, there was no statistically significant difference (P>0.05) in the mean CD8+ T-lymphocyte level in HIV 
positive subjects on ARV drugs (463.80208.10) and that of the control group.  On the contrary, there was a significant 
difference (p<0.05) between the mean CD8+ T-lymphocyte counts of diagnostic HIV positive subjects (449.20273.50) 
and that of HIV seronegative controls (613.20  258.20) (see Table 2).
The mean CD4/CD8 T-lymphocyte ratios of diagnostic HIV subjects (0.7670.661) and HIV seronegative control subjects 
(1.8670.723) as presented in table 3 below, showed a statistically significant difference (P<0.05) at 5% level of 
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significance.  Also, between HIV positive subjects on ARV drugs and HIV seronegative control groups, the mean 
CD4/CD8 ratios (0.6470.471 and 1.8670.723 respectively) was significantly different (P<0.05) at 5% level of 
significance.  On the other hand, the comparison between the mean CD4/CD8 T-lymphocyte ratios of diagnostic HIV 
positive subjects (0.7670.660) and that of HIV positive subjects (0.6470.471) on ARV drugs showed no significant 
difference (p>0.05).
Table 2: CD8+ T-lymphocyte levels in diagnostic HIV positive subjects, HIV positive subjects on ARV drugs and 
HIV Seronegative control subjects.
Parameters (cells/l) Diagnostic HIV ARV Drugs HIV Seronegative
Median 405.50 407.50 562.00
Mean 449.20 463.80 613.20
Standard Deviation 273.50 208.10 258.20
Minimum 89.00 196.00 289.00
Maximum 1355.00 1048.00 1086.00
Normality No Yes No
Table’s statistics for Dunn's Multiple Comparison Test: (1) Diagnostic (449.20273.50) vs ARV (463.80208.10); 
Difference in rank sum = -3.883 (P > 0.05). (2) Diagnostic (449.20273.50) vs Control (613.20258.20); 
Difference in rank sum = -17.67 (P < 0.05). (3) ARV(463.80208.10) vs Control (613.20258.20); Difference in 
rank sum = -13.78 (P > 0.05)
Table 3: CD4/CD8 T-Lymphocyte Ratio in Diagnostic HIV positive subjects, HIV positive subjects on ARV Drugs 
and HIV Seronegative control subjects.
Parameters Diagnostic HIV ARV Drugs HIV Seronegative
Median 0.50 0.50 1.65
Mean 0.77 0.65 1.87
Standard Deviation 0.66 0.47 0.72
Minimum 0.10 0.20 0.90
Maximum 2.70 1.90 3.40
Normality Test No No Yes
Table’s statistics for Dunn's Multiple Comparison Test: (1) Diagnostic (0.770.66) vs ARV (0.650.47); Difference 
in rank sum = 2.650 (P>0.05). (2) Diagnostic (0.770.66) vs Control (1.870.72); Difference in rank sum = -35.05 
(P<0.05). (3) ARV(0.650.47) vs Control(1.870.72); Difference in rank sum = -37.70 (P<0.05)
Table 4: Quantitative HIV virus in Diagnostic HIV Positive Subjects and HIV positive subjects on Antiretroviral 
Drugs (HAART).
Parameters (copies/ml) Diagnostic HIV ARV Drugs 
Median 20646.00 0.00
Mean 145591.00 24407.00




* Medians were significantly different (P < 0.05)
The mean viral load of HIV positive subjects on ARV drugs (145591.00259499.00) was significantly reduced when 
statistically compared with that (24407.00106479.00) of diagnostic HIV positive subjects (p<0.05).
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DISCUSSION
Specific cytotoxic CD8+ T-cells kill HIV-infected cells with the help of CD4+ T-lymphocytes that are needed to prime 
CD8+ T-cell responses and maintain both immunologic memory and cytolytic response.  During acute HIV infection, CD8+
T-cell count increases up to 20-folds with a vigorous specific anti-HIV response (Koup et al., 1994). The observed 
significant decrease of CD8+ T-cell count in diagnostic HIV-positive subjects with respect to that of HIV-seronegative 
control group may be associated with the decrease in the CD4+ T-lymphocyte counts of the diagnostic HIV-positive 
subjects.  Depletion of CD4+ T-cell count and its dysfunctional activity leads to decrease in the ability to recognize and 
respond to the HIV peptides on the surface of antigen presenting cells (APC), which may lead to low CD4+ T-cell 
activation and adversely affect CD8+ T-cell activation and proliferation, and specific cytotoxic CD8+ T-cell killing of HIV-
infected cells.  This dysfunctional activity may give HIV allowance to proliferate, increase the viral load, infect more cells, 
deplete more CD4+ T-cells and possibly cause permanent injury to the immune system.
Also, administration of antiretroviral drug (HAART) may cause reduction in the viral load, elevation of CD4+ T-cells and 
possibly activate CD8+ T-cells for proliferation and cytolytic activities (Kostense et al., 2002). This may be the reason for 
the observed non-significant difference between the CD8+ T-cell count in HIV-positive subjects on antiretroviral drugs and 
that of the HIV-seronegative control group in this study.  Such finding may imply that highly active antiretroviral therapy 
has tried to restore the immune response by up-regulating the CD4+ T-cell and cytotoxic T-lymphocytes quantitatively and 
qualitatively.  This may probably be emphasized by the observed significant reduction in the plasma viral load of the HIV-
positive subjects on antiretroviral drugs when compared with those of the diagnostic HIV-positive subjects. Though there 
was an elevation of mean CD4 T-lymphocyte count during antiretroviral drug intervention, there was no statistical 
significant deference when compared with that of the Diagnostic HIV positive subjects.  
Moreover, the number of circulating CD4+ T-cells is widely used to monitor the degree of immune suppression in HIV 
infection and provides a predictor of the immediate risk for opportunistic illness (Chiappini et al., 2006).  In early HIV 
infection, CD8+ T-cell number tends to increase, reflecting expansion of memory CD8+ T-cells, particularly HIV-specific 
CD8+ T-cells.  In contrast to this, the proportion of naive CD8+ T-cells tend to fall in early infection but absolute number of 
CD8+ T-cell do not fall until HIV disease progresses (Chinen et al., 2001).  In the present study, the CD4/CD8 ratio 
significantly reduced in both diagnostic HIV-positive subjects and HIV positive subjects on antiretroviral therapy 
compared with the CD4/CD8 ratio of HIV-seronegative control subjects. This finding may be as a result of persistent 
destruction of CD4+ T-cells throughout the stages of HIV disease (Day et al., 2006).  Absolute fall in CD4+ T-cells count in 
relation to CD8+ T-cells count may result to the fall in CD4/CD8 ratio observed in this study. This may be attributed to the 
infection of HIV virus to the progenitor cells of CD4 T-lymphocytes especially during progressive HIV infection. Such 
infection, with consistent activation and cytolysis may have impacted a permanent injury to proliferative capacity of the 
progenitor T-helper cells. Clearance of the virus from the system may not be good enough to effect a complete restoration
of immune response. This observation may contribute to the fact that a stable HIV patient who is on antiretroviral drug 
goes back to a critical condition almost immediately after withdrawal of drug intervention which was observed from 
defaulters or non-adherents. 
CONCUSION
HIV infection causes depletion of CD4 T-lymphocyte. Though, clearance of HIV particles or reduction in viral load by 
antiretroviral drug intervention lead to increase in the mean CD4 T-lymphocyte count and restoration of physiological 
condition of the subjects, there was no significant difference between the mean CD4 T-lymphocyte count of HIV positive 
subjects on antiretroviral drug and that of the Diagnostic HIV positive subjects. There may be a proliferative defect 
inflicted on the progenitor cells by the virus infection during progressive HIV disease.
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